Facing potential headwinds from a growing cultural counter-movement against long-term pediatric stimulant use and a shift toward unmedicated living.

As a key player in the ADHD market with Adderall, the company is positioned at the start of the 'drug cascade', which exposes it to a 'gateway' drug risk and ties its portfolio directly to the narrative of over-medication.